3 Drugs Stocks Driving The Industry Higher

TheStreet highlights 3 stocks pushing the health services industry higher today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 29 points (-0.2%) at 17,702 as of Tuesday, Nov. 10, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,315 issues advancing vs. 1,646 declining with 122 unchanged.

The Drugs industry currently sits down 0.8% versus the S&P 500, which is down 0.3%. Top gainers within the industry include

Intercept Pharmaceuticals

(

ICPT

), up 10.3%,

Opko Health

(

OPK

), up 5.0% and

Gilead

(

GILD

), up 0.8%. On the negative front, top decliners within the industry include

Dr Reddy Laboratories

(

RDY

), down 11.8%,

Halozyme Therapeutics

(

HALO

), down 11.0%,

Anacor Pharmaceuticals

(

ANAC

), down 6.2%,

Mallinckrodt

(

MNK

), down 6.0% and

Jazz Pharmaceuticals

(

JAZZ

), down 4.3%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Abbott Laboratories

(

ABT

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Abbott Laboratories is up $0.40 (0.9%) to $45.45 on light volume. Thus far, 2.1 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.6 million shares. The stock has ranged in price between $45.06-$45.62 after having opened the day at $45.07 as compared to the previous trading day's close of $45.05.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $68.1 billion and is part of the health care sector. Shares are up 0.1% year-to-date as of the close of trading on Monday. Currently there are 12 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Abbott Laboratories

as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, increase in stock price during the past year, impressive record of earnings per share growth and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Abbott Laboratories Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Eli Lilly and

(

LLY

) is up $0.55 (0.7%) to $79.41 on light volume. Thus far, 1.0 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $78.71-$79.75 after having opened the day at $78.71 as compared to the previous trading day's close of $78.86.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $89.2 billion and is part of the health care sector. Shares are up 15.0% year-to-date as of the close of trading on Monday. Currently there are 7 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Eli Lilly and

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Eli Lilly and Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Allergan

(

AGN

) is up $3.65 (1.2%) to $300.47 on light volume. Thus far, 681,304 shares of Allergan exchanged hands as compared to its average daily volume of 4.1 million shares. The stock has ranged in price between $296.17-$302.83 after having opened the day at $297.00 as compared to the previous trading day's close of $296.82.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. Allergan has a market cap of $118.7 billion and is part of the health care sector. Shares are up 15.3% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Allergan a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates

Allergan

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

Allergan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...